pTau217 Biomarker Assay

Frontage introduces a new ultrasensitive assay for the quantitative determination of pTau217 in human plasma, serum, and cerebrospinal fluid (CSF), one of the most promising blood-based biomarkers of Alzheimer’s disease.

Thank you for registering!

You now have the option of downloading the resource or viewing the web version below.